AVXS Avexis, Inc. (delisted)

Gene-therapy companies got a boost during Monday trading after Novartis AG's (NVS) $8.7 billion deal to buy AveXis Inc. (AVXS), making good on CEO Vasant Narasimhan's promise to strike deals to refocus the company. Analysts at Chardan said Regenxbio Inc. (RGNX), Spark Therapeutics Inc. (ONCE) and Nightstar Therapeutics PLC (NITE) could be among the company's next targets. Regenxbio shares jumped 22% to $33.05 during Monday trading, while Spark shares rose 14% to $70.75 and rand Nightstar rose 8.1% to $12.65. (imani.moise@wsj.com; @moisenoise)

(END) Dow Jones Newswires

April 09, 2018 12:44 ET (16:44 GMT)

AVEXIS, INC. (NASDAQ:AVXS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

AVEXIS, INC. (NASDAQ:AVXS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024